Stock Taper
SCREENER COMPARE ANY 2 STOCKS
PRTA
PROTHENA CORPORATION PLC
NASDAQ
$9.45
▲ UP 4.65% (0.42)

KEY STATISTICS

Market Cap$494.74 M
52w High$11.80
52w Low$7.73
Dividend Yield—
Frequency—
P/E-11.39
Volume376.04K
Shares Out.52.35M

COMPANY

LEADERSHIP

Gene G. Kinney
CHIEF EXECUTIVE
Gene G. Kinney

COMPENSATION 2026

Salary$692,973
Stock Awards$961,800
Incentive Plan Pay$415,784
All Other Comp.$15,750
Total$5,896,045

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 20, 2012
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
67

PRICE TARGET

Target High$30.00
Target Low$19.00
Target Median$24.50
Target Consensus$24.50

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$9.58M
NOV
5
THU

PRICE

$9.45 ▲ UP 4.65% (+$0.42)
$9.15$9.30$9.459:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM9.45

About Prothena Corporation plc

https://www.prothena.com ↗

Prothena Corporation plc is a late-stage clinical biotech developing novel therapies for serious diseases like amyloidosis, Parkinson's, and Alzheimer's, with ongoing Phase I-III trials and collaborations with Roche and Bristol-Myers.

INDUSTRY

Biotechnology

A PRODUCT PROTHENA CORPORATION PLC IS KNOWN FOR

Prasinezumab
Prasinezumab

Prothena's most advanced clinical-stage asset, a humanized monoclonal antibody targeting alpha-synuclein, is in Phase 2b trials for Parkinson's disease, developed in collaboration with Roche.

COMPETITORS

COMPETITOR
ABBV COMPARE
ACIU COMPARE
ANVS COMPARE
BIIB COMPARE
DNLI COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
License— $0 $50.05M ▲—
Collaboration$2.42M $21K ▼$1.03M ▲$1.01M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
88
LISTED HERE
17
RANKED BY POSITION SIZE
XBI
0.12% · 1.5M
IWM
0.01% · 1.1M
VXF
0.00% · 481.6K
SCHA
0.01% · 200.2K
DFMC
0.02% · 169.5K
FSCC
0.44% · 164.3K
AVSC
0.02% · 85.5K
LABU
0.08% · 60.6K
XRSG.L
0.01% · 38.4K
BBC
0.67% · 37.7K
GSSC
0.03% · 37.4K
PRFZ
0.01% · 34.5K
RSSL
0.01% · 21.1K
MNTL
0.42% · 6.4K
URTY
0.01% · 1.8K
VETS
0.03% · 814
RESM
0.01% · 90

INSTITUTIONAL OWNERSHIP

SHARES OWNED
69.89%
HOLDERS
310
TOP 12 OF 310 · RANKED BY POSITION SIZE
Fmr LLC
7.9M sh · $77.12M
Rubric Capital Management LP
5.0M sh · $48.95M
Blackrock, Inc.
4.9M sh · $47.66M
Blackrock Inc.
3.9M sh · $79.61M
State Street Corp
2.4M sh · $23.43M
Armistice Capital, LLC
2.2M sh · $13.57M
Vanguard Group Inc
2.1M sh · $20.45M
Acadian Asset Management LLC
2.0M sh · $19.68M
D. E. Shaw & Co., Inc.
1.8M sh · $17.14M
Adar1 Capital Management, LLC
1.6M sh · $15.37M
Blackrock Fund Advisors
1.5M sh · $74.53M
Palo Alto Investors LP
1.3M sh · $12.92M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
10 PERCENT OWNER
SCULLY WILLIAM P
Purchase · 50.0K shares
2026-08-20
★
10 PERCENT OWNER
SCULLY WILLIAM P
Purchase · 336.0K shares
2026-08-17
★
10 PERCENT OWNER:
Fennell Todd W.
— · —
2026-08-18
★
10 PERCENT OWNER
SCULLY WILLIAM P
Sale · 627.6K shares
2026-08-18

MOST RECENT ANALYST GRADES

GRADE SUMMARY
MARKET OUTPERFORM 2
BUY 2
SECTOR PERFORM 1
OVERWEIGHT 1
6 GRADES IN THE LAST 12 MONTHS
Citizens MARKET OUTPERFORM RBC Capital SECTOR PERFORM HC Wainwright & Co. BUY Piper Sandler OVERWEIGHT JMP Securities MARKET OUTPERFORM Chardan Capital BUY

SECTORS PEERS

PEERPRICE
CRVS$14.46COMPARE
OLMA$10.69COMPARE
RIGL$45.89COMPARE
FDMT$15.83COMPARE
VSTM$6.89COMPARE
BCYC$4.37COMPARE
NMRA$1.63COMPARE
GOSS$0.15COMPARE